Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.
about
Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and TechnologiesLong-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapyAdjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERα- breast cancer.Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.IDICAP: A Novel Tool for Integrating Drug Intervention Based on Cancer Panel.The evolving understanding of small HER2-positive breast cancers: matching management to outcomes.Trastuzumab in the Treatment of Breast Cancer.Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany.Adjuvant trastuzumab: a 10-year overview of its benefit.Oncogenic signaling of MEK5-ERK5.Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine.Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan.Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer.Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans.The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.Aryl Hydrocarbon Receptor Diet and Breast Cancer Risk.
P2860
Q26783705-F476FAD7-6889-4C41-A7F9-35E02B1859C5Q35580011-E55AE454-8CC6-4C7C-9500-17DC27C8CF56Q36098713-5148983E-49AA-4366-BB7D-AE6F995D4B11Q36410466-5ED951BE-9DB9-484F-BB18-B5AB18E78770Q37022428-DFD082EA-A601-4FAC-B31E-4BB58F4084DFQ37542355-2373EAE8-D550-4212-A492-C1DD1C433000Q38658647-EBEA947E-65EE-4BE4-9C02-33FFE5455EC9Q38739914-4DE08C79-5AAF-489C-90F8-69BFC4CED8B2Q38973381-339A4928-5A74-45CD-A77E-B9D37F05AAF6Q39018742-DECE9D8E-3F99-4F3E-A08B-0CEC52253CB3Q39116456-031E8AEF-7A0C-46E6-B3A9-3385A4A22086Q39346715-5BAE8CD1-A250-426A-A368-309C1097574AQ39389369-2AA2C581-25C0-4655-B921-110E17575CEBQ47144472-BF8E93EE-F324-4494-B69A-2135CEBA80DBQ48056637-B58C010D-C09E-4A70-8C6A-BF12F33B0E09Q48202060-0C66178E-20B4-47F2-8F87-90E469DC33D9Q48256716-C698DCFA-04FE-4EAA-B345-36C37D7B3717Q51673307-222AD13B-6BC2-4548-9482-4BAAC9B1A40FQ55349797-9882D947-FC8E-461F-B99E-2DA5AED4EF7C
P2860
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Efficacy of Adjuvant Trastuzum ...... Randomized Trastuzumab Trials.
@ast
Efficacy of Adjuvant Trastuzum ...... Randomized Trastuzumab Trials.
@en
type
label
Efficacy of Adjuvant Trastuzum ...... Randomized Trastuzumab Trials.
@ast
Efficacy of Adjuvant Trastuzum ...... Randomized Trastuzumab Trials.
@en
prefLabel
Efficacy of Adjuvant Trastuzum ...... Randomized Trastuzumab Trials.
@ast
Efficacy of Adjuvant Trastuzum ...... Randomized Trastuzumab Trials.
@en
P2093
P2860
P50
P356
P1476
Efficacy of Adjuvant Trastuzum ...... Randomized Trastuzumab Trials.
@en
P2093
Christine Campbell
Ciara C O'Sullivan
Dimitrios Zardavas
Edith A Perez
Eileen Holmes
Heikki Joensuu
Ian Bradbury
Jo Anne Zujewski
Joseph P Costantino
Karla V Ballman
P2860
P304
P356
10.1200/JCO.2015.60.8620
P407
P577
2015-06-22T00:00:00Z